CD24 and cancer: Preclinical studies have identified CD44<sup>+</sup>CD24<sup>-/low</sup> as a cancer stem cell phenotype; however, clinical studies have reported seemingly controversial results regarding the prognostic values of CD44 and CD44<sup>+</sup>CD24<sup>-/low</sup> phenotype in TNBC patients.